Bimagrumab: The Drug That Makes Weight Loss All Fat
The biggest unsolved problem with GLP-1 medications is that roughly a third of what you lose is muscle. Bimagrumab attacks that directly - and in trials it did something no weight loss drug has done before: produced weight loss where every pound came from fat, while lean mass went up.
Last updated: August 3, 2026
Bimagrumab Is Not Approved
Bimagrumab is investigational - it is not FDA approved, not available by prescription, and cannot be obtained legally for weight loss. It is a monoclonal antibody, so it also cannot be meaningfully replicated by compounding. Everything below is research, not a treatment option. The proven muscle-preservation tools available today are protein and resistance training, covered at the end.
Quick Answer
Bimagrumab is an antibody that blocks activin type II receptors, and the Phase 2 results are genuinely unusual. Taken alone it produced 10.8% total weight loss with 100% of that coming from fat mass - and lean mass actually increased by 2.5%.
Combined with semaglutide 2.4 mg, bimagrumab 30 mg/kg produced more than 20% weight loss at 72 weeks while preserving lean mass despite achieving greater fat reduction, including intra-abdominal fat. Earlier data showed a 20.5% decline in fat mass, a 3.6% increase in lean mass, and a 9 cm waist reduction.
The context that makes this matter: interim results from the Phase 2 COURAGE trial found that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.
The 35% Problem
Every GLP-1 article quotes a weight loss percentage. Almost none tell you what that weight is made of.
Interim results from the Phase 2 COURAGE trial put a number on it: approximately 35% of semaglutide-induced weight loss was due to loss of lean mass. Roughly a third of what comes off is not fat.
That matters for several reasons that compound over time:
- Lower resting metabolic rate. Muscle is metabolically active tissue. Losing it means burning fewer calories at rest, which makes maintaining your loss harder.
- Worse body composition at the same weight. Two people at 180 lbs with different lean mass look and function very differently.
- Functional decline with age. Muscle loss compounds with age-related sarcopenia, raising fall and fracture risk - particularly relevant after menopause.
- Harder maintenance. Less muscle makes weight regain after stopping more likely, and this class already has a regain problem.
This is why we have written about protein and resistance training on nearly every page. Not as generic wellness advice - because a third of your weight loss being muscle is a real, measured problem with a real solution. See our muscle loss prevention guide.
How Bimagrumab Works
Bimagrumab is not a GLP-1 drug and does not work on appetite at all. It is a monoclonal antibody that blocks activin type II receptors.
Those receptors are part of a signalling system that limits muscle growth - myostatin, the best-known member of that family, acts as a brake on muscle mass. Block the receptor and you release the brake, allowing muscle to be built and maintained even in a calorie deficit where it would normally be broken down.
| Drug Class | What It Does | Effect on Lean Mass |
|---|---|---|
| GLP-1 agonists | Reduce appetite and food intake | Lost alongside fat - roughly 35% of total |
| Bimagrumab | Blocks activin type II receptors | Preserved or increased |
They are complementary rather than competing mechanisms - one reduces intake, the other protects what you keep. That is exactly why the combination trials were run.
Bimagrumab Alone: The Remarkable Result
The monotherapy arm produced a result with no real precedent in obesity pharmacology.
| Outcome | Bimagrumab Alone |
|---|---|
| Total weight loss | 10.8% |
| Share of weight loss from fat | 100% |
| Change in lean mass | Increased 2.5% |
Read that carefully. Every pound lost was fat, and muscle went up. That is a fundamentally different kind of result from a scale number - and it explains why earlier work reported a modest-sounding net 6.5% reduction in body weight despite a large fat reduction: gained muscle partly offset lost fat on the scale.
This is the clearest illustration of why scale weight is a poor metric. Someone losing 20.5% of their fat mass while gaining 3.6% lean mass and dropping 9 cm from their waist would see a fairly unimpressive number on the scale - and would be transformed. If you take one idea from this page, make it that. See our guide on measuring progress properly.
Combined With Semaglutide
The combination is where this becomes clinically interesting, and it was studied in the Phase 2 BELIEVE trial, with results published in Nature Medicine.
| Outcome | Bimagrumab 30 mg/kg + Semaglutide 2.4 mg |
|---|---|
| Total weight loss at 72 weeks | More than 20% |
| Fat mass | Greater reduction than semaglutide alone, including intra-abdominal fat |
| Lean mass | Preserved despite the greater fat loss |
Combination treatment led to superior fat mass loss while simultaneously preserving lean mass. The intra-abdominal detail matters - visceral fat is the metabolically harmful kind, so reducing it preferentially is exactly what you would want. See our visceral fat guide.
More than 20% total weight loss puts the combination in tirzepatide territory - but with a body composition profile no current drug achieves.
Why Body Composition Beats Scale Weight
Bimagrumab research is quietly changing how the field talks about obesity drugs. For a decade the competition has been a percentage race - 15%, 20%, 22%, 30%. Bimagrumab reframes the question as what is that weight made of.
| Scenario | Scale change | Actual outcome |
|---|---|---|
| 20% loss, 35% of it lean mass | Impressive | Lower metabolic rate, harder maintenance |
| 10.8% loss, 100% fat, lean mass up | Modest | Better composition, better metabolic rate |
The second row is the better outcome despite the worse headline number. That has a practical implication available to you right now: if you are on a GLP-1 and the scale stalls while your waist keeps shrinking, that may be the good version of a plateau - fat coming off while lean mass holds or builds from resistance training.
Open Questions
- Phase 3 has to confirm it. These are Phase 2 results. Effect sizes routinely shrink in larger, longer trials.
- Long-term safety of blocking this pathway is not established. Activin signalling does more than limit muscle growth, and chronically blocking a regulatory system requires careful long-term study.
- It is an antibody, which means cost. Monoclonal antibodies are expensive to manufacture. If approved, pricing may be well above current GLP-1s.
- Is added muscle functional? Increased lean mass on a scan is encouraging, but strength and function outcomes matter more than the number.
- No approval date exists. Nothing about the timeline is announced.
And the obvious warning: bimagrumab is a monoclonal antibody, not a peptide. Anything sold online claiming to be bimagrumab is not a legitimate product, and antibodies cannot be replicated by compounding pharmacies. See our note on gray-market research compounds.
What You Can Do Today
Bimagrumab is years away. But the problem it addresses is happening to you right now if you are on a GLP-1 - and the proven interventions are unglamorous and free.
- Resistance training two to three times weekly. This is the single most effective muscle-preservation intervention available, and it is not optional at these rates of weight loss.
- Protein at roughly 0.7-1.0 g per pound of goal body weight daily, spread across meals. Track it for a week - appetite suppression means most people eat far less than they assume.
- Do not chase fast loss. Roughly 1-2% of body weight per month. Faster costs disproportionately more lean mass.
- Measure body composition, not just weight. A DEXA scan at baseline and six months tells you what you are actually losing. Waist circumference is a decent free proxy.
- Do not escalate dose reflexively. If you are losing steadily and tolerating your dose, going higher accelerates loss - including lean mass.
The honest summary: bimagrumab may eventually do pharmacologically what resistance training and adequate protein already do reasonably well. You do not need to wait for it - you need to lift and eat protein. Full protocol in our muscle loss prevention guide.
Frequently Asked Questions
What are the Phase 2 results for bimagrumab?
Taken alone, bimagrumab produced 10.8% total weight loss with 100% of it coming from fat mass and lean mass increasing by 2.5%. Combined with semaglutide 2.4 mg, bimagrumab 30 mg/kg produced more than 20% weight loss at 72 weeks while preserving lean mass despite greater fat reduction, including intra-abdominal fat. Earlier data showed a 20.5% fat mass decline, 3.6% lean mass increase, and 9 cm waist reduction.
How much of GLP-1 weight loss is muscle?
Interim results from the Phase 2 COURAGE trial found approximately 35% of semaglutide-induced weight loss was due to loss of lean mass - roughly a third of what comes off is not fat. This lowers resting metabolic rate, makes maintenance harder, and compounds with age-related muscle loss. It is why protein intake and resistance training matter so much on these medications.
How does bimagrumab work?
It is a monoclonal antibody that blocks activin type II receptors. Those receptors are part of a signalling system - including myostatin - that acts as a brake on muscle growth. Blocking the receptor releases that brake, allowing muscle to be maintained or built even in a calorie deficit where it would normally break down. It does not affect appetite at all, which is why it complements rather than competes with GLP-1 drugs.
When will bimagrumab be available?
No approval date has been announced. The results discussed here are Phase 2, and Phase 3 trials must confirm them before any regulatory submission - effect sizes routinely shrink in larger, longer studies. Long-term safety of chronically blocking activin signalling also needs establishing. Realistically this is years away, if it arrives at all.
Can I buy bimagrumab?
No. It is investigational, not FDA approved, and not available by prescription. It is also a monoclonal antibody rather than a peptide, which means it cannot be replicated by a compounding pharmacy - anything sold online under this name is not a legitimate product and should be avoided entirely.
Why was total weight loss only 6.5% in some bimagrumab data?
Because gained muscle offsets lost fat on the scale. One trial reported a net 6.5% body weight reduction alongside a 20.5% decline in fat mass and a 3.6% increase in lean mass. The scale number looks modest while the body composition change is substantial - which is exactly why scale weight alone is a poor measure of what a weight loss intervention is doing.
What can I do about muscle loss now?
Resistance training two to three times weekly is the single most effective intervention available, and protein at roughly 0.7-1.0 g per pound of goal body weight daily is second. Avoid chasing rapid loss - 1-2% of body weight per month is the sustainable range, and faster costs disproportionately more lean mass. Consider a DEXA scan at baseline and six months to see what you are actually losing.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Bimagrumab is an investigational drug that has not been approved by the FDA and is not available by prescription. Nothing here should be interpreted as encouragement to obtain it from any source. Clinical trial figures come from Phase 2 studies; effect sizes and safety profiles commonly change in larger Phase 3 trials and do not predict individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or weight loss strategy. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.